The approval of commercial application transcatheter aortic valve replacement (TAVR) by the FDA in 2011 has revolutionized the management of high-risk surgical patients with severe aortic stenosis (AS). With TAVR being expanded to intermediate surgical risk patients in 2016, the number of patients undergoing TAVR has been increasing rapidly. In fact, since the very first human TAVR procedure in 2002, more than 300,000 TAVRs have been performed worldwide. [1, 2] The technological advancements in the TAVR since its early days of clinical adaptation has made this procedure a routine practice in many institutions worldwide. However, one of the most feared complications, ischemic stroke, remains a major concern for clinicians and patients despite all the advancements in the procedure.  The incidence of periprocedural stroke for TAVR varies, ranging from 3% to as high as 11%, depending on the source. [38] The risk of stroke 30 days post-TAVR was found to be 5.5% in the PARTNER (Placement of Aortic Transcatheter Valves)-2 trial. [8] A meta-analysis with 10,037 patients undergoing TAVR in various studies reported a total stroke rate of 3.3% ± 1.8% at 30 days, and 5.2% ± 3.4% at 1 year. [6] Similarly, Kleiman, et al. [7] reported a major stroke rate of 2.8% for TAVR patients at 30 days, and 5% at 1 year. Regardless of the exact incidence, major stroke following TAVR has been shown to be associated with increased early and late mortality. [9, 10] In the same meta-analysis with 10,037 patients, Eggebrecht, et al. [6] reported the average 30-day mortality was more than 3.5 times higher in patients with stroke. In another meta-analysis of 29,034 patients, 30-day post-TAVR mortality following a stroke was quoted to be as high as 12.27% compared to 6.4% for patients without a stroke. [11] There is growing evidence that the actual stroke rate post-TAVR has been drastically underestimated due to the variability of the clinical definition of stroke. Most recent # Correspondence to: hualiu@ucdavis.edu data estimated an incidence of subclinical new cerebral ischemic lesions to be 68%100% following TAVR procedures based on neuroimaging with diffusion weighted imaging MRI (DWI-MRI). [2,10,1215] The significance of these "silent infarctions" remains: remains unclear as it is difficult to assess cognitive status in this patient population with varying comorbidities, especially immediately following procedures that involve sedation or general anesthesia. The bigger question surrounding such findings is whether these silent infarctions have any significant long-term clinical impacts post-TAVR. One study entailing DWI-MRI neuroimaging on post-TAVR patients suggested they do. The study showed brain lesions were detected in 94% of patients, with 41% of the patients with cognitive deviation from baseline at 30-days post-discharge using the Montreal cognitive assessment tool. [16] It has been suggested that the presence of these silent lesions may be related to memory loss, cognitive decline or dementia. [17] Given the high incidence of silent cerebral embolic lesions, the potential longterm clinical impact of periprocedural "silent infarctions", and the continuous expansion of the procedure to cover younger and lower risk patients, peri-TAVR stroke prevention has become one of the major focuses of the TAVR procedure.
Studies have shown that release of atherosclerotic or valvular emboli into the cerebral circulation is considered to be a significant cause of stroke during TAVR likely secondary to catheter manipulation around the atherosclerotic aorta and across the calcified aortic valve. [6, 18] As such, several efforts have focused on identifying novel stroke prevention strategies to improve the overall outcomes of TAVRs, ranging from identifying and modifying the patients' clinical risk factors to the development of mechanical embolic protection devices (EPDs). Various EPDs have been recently developed with the aim to help reduce or prevent the occurrence of periprocedural embolic lesions in TAVR patients. The general mechanism of these devices involves percutaneous deployment of a porous membrane apparatus at the level of the aortic arch or great vessels, which can then either filter or deflect emboli to the central nervous system during TAVR (Table 1) .
Of the four major EPDs, the Sentinel device (Claret Medical Inc.) was the first device to receive Food and Drug Administration (FDA) approval for use in TAVR in the U.S (Figure 1 ). [2, 19] This device was studied in the MISTRAL-C trial, a multicenter, double-blind, randomized control trial with 63 patients undergoing TAVR with or without the device. [20] The results showed the device group had fewer new brain lesions and a smaller total lesion volume (95 vs. 197 mm 3 ) than the control group. In addition, neurocognitive deterioration was quoted to be less in the device group (4% vs. 27%). Another recent prospective study with 802 patients involving the Sentinel device showed the rate of disabling and nondisabling stroke was significantly reduced from 4.6% to 1.4% [absolute risk reduction 3.2%; number needed to treat (NNT) 31]. [21] The study also showed a reduction in all-cause mortality or all-stroke within 7 days in the protected group compared to the control group, 2.1% vs. 6.8% respectively (absolute risk reduction 4.7%; NNT 21). [21] However, the jury is still out regarding the clinical significance of EPDs in TAVR patients. A recent meta-analy-sis by Mohananey and colleagues, which included 6 studies with a total of more than 1,200 patients, concluded that there is no difference between patients with and without embolic protection in terms of stroke and mortality at 30-days post TAVR. [19] A similar systematic review and meta-analysis with over 1200 patients and eight studies also concluded that the use of EPDs does not reduce 30-day mortality or reduce the rate of new lesions as assessed by MRI, but may reduce the total cerebral ischemic volumes. However, their results suggested that the use of EPDs seems to be associated with a lower 30-day stroke rate. [17] Another prospective randomized control trial with the Sentinel protection device showed no statistical difference in neurocognitive outcome in the device group compared to the control group. [22] However, the study did show a high device delivery and retrieval success rate (> 94%) along with consistency of retrieved embolic materials in almost all patients undergoing TAVR. [22] It also concluded that there is no difference in the incidences of major vascular complications, major bleeding, and acute kidney injury between the two groups, supporting the safety claim of the use of such EPDs. Study by Giustino and colleagues did, however, find that use of EPDs is associated with a lower risk of early deterioration of neurocognitive function. [23] The occurrence of TAVR related stroke demonstrates a bimodal pattern of distribution as evident by multiple studies in the past. [2, 9, 24, 25] According to these studies, predictors of early stroke include patients' demographics, clinical characteristics, and procedural factors. [7, 9] On the other hand, predictors of late stroke are primarily related to patients' frailty. [7, 9] As the embolic protection devices are only meant to reduce one specific cause of periprocedural stroke in TAVR patients, namely the procedural factors influencing the early stroke, the impact of these devices on the longterm clinical outcomes post-TAVR remains to be further delineated in future larger randomized controlled trials. Interestingly, carotid artery embolic protection for carotid stenting has become a requirement in high-risk patients for reimbursement from the Centers for Medicare and Medicaid Services in the U.S. [26] With the PARTNER 3 trial evaluating the efficacy of Edwards SAPIEN 3 valve for low surgical risk patients with AS showing the stroke rate is lower, [27] it is still important to prevent the stroke due to the large numbers of "silent infarctions" and its impact in long term outcomes.
In summary, there is not enough evidence to routinely recommend the use of cerebral embolic protection devices currently. However, these devices should be considered heavily in those at higher risk of embolic events given their relatively high safety profile. It may be challenging to compare the effectiveness of the various types of embolic protection devices as their placement technique, location and specific function differ. Additionally, assessing neurocognitive function before and after TAVR proves to be another difficult task as there lacks a standardized process of evaluating neurocognitive status in these patients. Certainly, as the TAVR population expands to include low to intermediate-and low-risk patients, there will likely be much more focus on the specific role EPDs and preventing clinically significant cerebral ischemic events.
